A Phase 1, Single Center, Biomarker Study in Healthy Subjects Receiving Single Doses of CAT-1004.

Trial Profile

A Phase 1, Single Center, Biomarker Study in Healthy Subjects Receiving Single Doses of CAT-1004.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Edasalonexent (Primary) ; Docosahexaenoic acid; Salsalate
  • Indications Duchenne muscular dystrophy; Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 11 Jan 2017 Primary endpoint (Change in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activity p65 following ex vivo lipopolysaccharide stimulation) has been met.
    • 11 Jan 2017 Combined results from three phase I trials published in the Journal of Clinical Pharmacology
    • 11 Feb 2013 Combined results from three phase I trials were reported in a Catabasis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top